SLC5A2 and obesity disorder: Interestingly, its most responsive subgroup included individuals with diabetes, obesity, and cardiovascular comorbidities., suggesting that SGLT2 inhibitors could be repurposed to target overlapping vascular and metabolic pathways implicated in AD.